INVO Fertility, Inc. Announces Restatement of Previously Issued Financial Statements for 2025
Key Points from the Form 8-K Filing
- Restatement of Financial Statements: INVO Fertility, Inc. (NASDAQ: IVF) has announced that it will restate its unaudited consolidated financial statements for the quarters ending March 31, June 30, and September 30, 2025.
- Nature of the Errors: The restatement is due to errors primarily related to highly technical derivative and debt extinguishment accounting. These errors affect assets, liabilities, equity, other income (expense), and net income (loss).
- Audit Committee Actions: On June 1, 2026, the audit committee, after considering management’s recommendations, determined that the previously issued financial statements for the affected periods should no longer be relied upon.
- Restatement Process: The corrections will be included in the forthcoming Annual Report on Form 10-K for the year ended December 31, 2025. The prior quarterly reports (Forms 10-Q) will NOT be amended, but future filings will present restated historical amounts for consistency.
- Communication with Auditors: The company’s management and audit committee have discussed these matters with its independent registered public accounting firm, WithumSmith+Brown, PC.
Detailed Issues Identified
- Incorrect classification of Series C-1 Preferred Stock, which should have been classified as mezzanine equity in Q1 2025.
- Incorrect classification of Series C-2 Preferred Stock, which should have been classified as mezzanine equity in Q2 2025.
- Incorrect accounting for a convertible debenture with an embedded derivative, which should have been bifurcated.
- Incorrect recognition of a gain on settlement and reduction of liabilities related to a binding term sheet in Q2 2025.
- Incorrect equity classification of common stock purchase warrants from a warrant inducement transaction in Q2 2025, which should have been classified as liabilities.
- Incorrect accounting for an amendment to a promissory note in Q3 2025, which should have been treated as a debt extinguishment under ASC 470-50.
Implications for Shareholders and Potential Price Sensitivity
- Material Non-Reliance: Shareholders should be aware that the company’s previously issued unaudited financial statements for the first three quarters of 2025 can no longer be relied upon. This is a significant event and may impact investor confidence and the company’s valuation.
- Restatement of Key Financial Metrics: The errors identified affect key financial line items, including assets, liabilities, equity, other income (expense), and net income (loss). This could have a material impact on the company’s reported performance for 2025.
- Regulatory Risk: Restatements of financial statements often attract scrutiny from regulators and could impact the company’s standing with investors, lenders, and business partners.
- Market Reaction: The announcement of a restatement, especially one involving complex accounting for derivatives and debt, is typically viewed negatively by the market and may lead to increased volatility in the share price.
- Ongoing Disclosure: The company will present the restated financial data in its next Form 10-K annual report. Investors should monitor upcoming filings closely for further details on the magnitude of the restatement.
Additional Company Information
- Company Name: INVO Fertility, Inc. (formerly known as NAYA Biosciences, Inc. and INVO Bioscience, Inc.)
- Trading Symbol: IVF
- Exchange: The Nasdaq Stock Market LLC
- Business Address: 5582 Broadcast Court, Sarasota, FL 34240
- Emerging Growth Company Status: The company is not an emerging growth company.
Conclusion
The restatement of previously issued financial statements is a material event for INVO Fertility, Inc. Investors should exercise caution and closely follow the company’s forthcoming annual report for more detailed information about the impact of these accounting errors on the company’s financial health and future prospects. The situation could potentially affect share price, and current and prospective shareholders are advised to stay updated as more information becomes available.
Disclaimer: This article is based on publicly available SEC filings and is provided for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The company’s upcoming filings may contain additional or updated information that could be material to investors.
